Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)(NCT02408042)
To determine the recommended phase 2 dose of chemotherapy in combination with pembrolizumab (formerly MK-3475 and lambrolizumab; Keytruda®/Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.) in subjects with advanced lymphoma and determine the complete response rate. Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
This trial is sponsored by Western Regional Medical Center. 
- Hodgkin’s Lymphoma
- Non-hodgkin’s Lymphoma
- Phase: I & II
- Estimated Enrollment: 30
- Start: April 2015
- Estimated Primary Completion: April 2016
- Last verified: April 2015
Last Editorial review: July 17, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.